Mineralys Therapeutics (NASDAQ:MLYS) Issues Earnings Results, Beats Estimates By $0.02 EPS

Mineralys Therapeutics (NASDAQ:MLYS) posted its quarterly earnings results on Wednesday. The company reported ($0.98) earnings per share for the quarter, topping the consensus estimate of ($1.00) by $0.02, Zacks reports.

Mineralys Therapeutics Stock Performance

Shares of NASDAQ MLYS traded up $0.30 during mid-day trading on Wednesday, hitting $9.96. The stock had a trading volume of 80,156 shares, compared to its average volume of 257,219. The firm has a market cap of $495.46 million, a P/E ratio of -3.05 and a beta of 1.44. The business has a 50 day moving average price of $11.31 and a two-hundred day moving average price of $12.06. Mineralys Therapeutics has a 1 year low of $8.58 and a 1 year high of $16.91.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Mineralys Therapeutics in a research note on Tuesday, November 12th.

Insiders Place Their Bets

In related news, CEO Jon Congleton sold 18,333 shares of the business’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $9.06, for a total transaction of $166,096.98. Following the transaction, the chief executive officer now owns 877,608 shares in the company, valued at $7,951,128.48. The trade was a 2.05 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Adam Scott Levy sold 10,757 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $9.10, for a total value of $97,888.70. Following the transaction, the chief financial officer now owns 226,097 shares in the company, valued at $2,057,482.70. This trade represents a 4.54 % decrease in their position. The disclosure for this sale can be found here. Insiders own 33.24% of the company’s stock.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.